Literature DB >> 36130252

The interruption of transmission of onchocerciasis in Kaduna, Kebbi and Zamfara states, Nigeria: another milestone achievement.

Sunday Isiyaku1, Michael Igbe2, Suzie Madaki1, Louise C Hamill3, Patrick Ndongmo4, William Adamani1, Simon Bush3, Joy Shu'aibu1, Elizabeth Elhassan1, Yisa Saka2, Chukwuma Anyaike2, Nse Michael Akpan2, Akilah Joel2, Audrey Nyior2, Alhassan Abdullahi5, Attahiru Aleiro6, Abdullahi Labbo7, Hayward Babale Mafuyai8, Bertram E B Nwoke9.   

Abstract

BACKGROUND: More than 40 million people live in onchocerciasis-endemic areas in Nigeria. For at least 19 y, mass drug administration (MDA) with ivermectin was implemented with at least 65% total population coverage in Kaduna, Kebbi and Zamfara states. Impact surveys done using skin biopsies yielded no infections. Serological and entomological assessments were undertaken to determine if onchocerciasis transmission had been interrupted and MDA could be stopped.
METHODS: The presence of onchocerciasis-specific immunoglobulin G4 antibody was measured by enzyme=linked immunosorbent assay conducted on dried blood spots collected from 5- to 9-year-old children resident in each state. O-150 polymerase chain reaction testing of Simulium damnosum s.l. heads for Onchocerca volvulus DNA was done on black flies collected by human landing capture and Esperanza window traps.
RESULTS: A total of 9078 children were surveyed across the three states. A total of 6139 vectors were collected from Kaduna state, 129 from Kebbi state and 2 from Zamfara state; all were negative. Kebbi and Zamfara states did thousands of hours of black fly catching and intensive river prospecting. The resulting low fly catch was due to a low fly population incapable of sustaining transmission.
CONCLUSION: Onchocerciasis transmission has been interrupted and the three states meet World Health Organization thresholds: seropositivity in children <0.1% and <1/2000 infective black flies with 95% confidence. The 2.2 million people in Kaduna state and 4 million in Kebbi and Zamfara states no longer need ivermectin for onchocerciasis.
© The Author(s) 2022. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.

Entities:  

Keywords:  zzm321990 Simuliumzzm321990 ; Ov16 serological assessment; black flies; entomological assessment; onchocerciasis; stopping mass drug administration

Mesh:

Substances:

Year:  2022        PMID: 36130252      PMCID: PMC9492257          DOI: 10.1093/inthealth/ihac036

Source DB:  PubMed          Journal:  Int Health        ISSN: 1876-3405            Impact factor:   3.131


  23 in total

1.  Impact of annual dosing with ivermectin on progression of onchocercal visual field loss.

Authors:  S N Cousens; A Cassels-Brown; I Murdoch; O E Babalola; D Jatau; N D Alexander; J E Evans; P Danboyi; A Abiose; B R Jones
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

2.  Onchocerciasis control in Nigeria.

Authors:  L D Edungbola
Journal:  Parasitol Today       Date:  1991-05

3.  Onchocerciasis and its control. Report of a WHO Expert Committee on Onchocerciasis Control.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1995

4.  Guide to detecting a potential recrudescence of onchocerciasis during the posttreatment surveillance period: the American paradigm.

Authors: 
Journal:  Res Rep Trop Med       Date:  2012-05-18

5.  Pool screen polymerase chain reaction for estimating the prevalence of Onchocerca volvulus infection in Simulium damnosum sensu lato: results of a field trial in an area subject to successful vector control.

Authors:  L Yamèogo; L Toè; J M Hougard; B A Boatin; T R Unnasch
Journal:  Am J Trop Med Hyg       Date:  1999-01       Impact factor: 2.345

6.  Operational Performance of the Onchocerca volvulus "OEPA" Ov16 ELISA Serological Assay in Mapping, Guiding Decisions to Stop Mass Drug Administration, and Posttreatment Surveillance Surveys.

Authors:  Frank O Richards; Moses Katabarwa; Firdaweke Bekele; Zerihun Tadesse; Aderajew Mohammed; Mauricio Sauerbrey; Alfredo Dominguez-Vazquez; Mario A Rodriguez-Perez; Nadia A Fernández-Santos; Nidia Rizzo; Harland R Schuler Martínez; Raquel Lovato Silva; Zoraida Morales Monroy; Peace Habomugisha; David W Oguttu; Issam M A Zarroug; Nabil A Aziz; Thomas R Unnasch
Journal:  Am J Trop Med Hyg       Date:  2018-07-12       Impact factor: 2.345

7.  Oligonucleotide based magnetic bead capture of Onchocerca volvulus DNA for PCR pool screening of vector black flies.

Authors:  Hemavathi Gopal; Hassan K Hassan; Mario A Rodríguez-Pérez; Laurent D Toé; Sara Lustigman; Thomas R Unnasch
Journal:  PLoS Negl Trop Dis       Date:  2012-06-19

8.  Evaluation of Community-Directed Operation of Black Fly Traps for Entomological Surveillance of Onchocerca volvulus Transmission in the Madi-Mid North Focus of Onchocerciasis in Northern Uganda.

Authors:  Denis Loum; Charles R Katholi; Thomson Lakwo; Peace Habomugisha; Edridah M Tukahebwa; Thomas R Unnasch
Journal:  Am J Trop Med Hyg       Date:  2017-10       Impact factor: 3.707

9.  The Imaramagambo Onchocerciasis Focus in Southwestern Uganda: Interruption of Transmission After Disappearance of the Vector Simulium neavei and Its Associated Freshwater Crabs.

Authors:  Moses N Katabarwa; James Katamanywa; Thomson Lakwo; Peace Habomugisha; Edson Byamukama; David Oguttu; Christine Nahabwe; Monica Ngabirano; Ephraim Tukesiga; Annet Khainza; Edridah Tukahebwa; Thomas R Unnasch; Frank O Richards; Rolf Garms
Journal:  Am J Trop Med Hyg       Date:  2016-05-23       Impact factor: 2.345

10.  The Interruption of Transmission of Human Onchocerciasis by an Annual Mass Drug Administration Program in Plateau and Nasarawa States, Nigeria.

Authors:  Frank O Richards; Abel Eigege; John Umaru; Barminas Kahansim; Solomon Adelamo; Jonathan Kadimbo; Jacob Danboyi; Hayward Mafuyai; Yisa Saka; Gregory S Noland; Chukwuma Anyaike; Michael Igbe; Lindsay Rakers; Emily Griswold; Thomas R Unnasch; B E B Nwoke; Emmanuel Miri
Journal:  Am J Trop Med Hyg       Date:  2020-03       Impact factor: 3.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.